Summary The present paper describes two immunoconjugates consisting of an anti-epidermal growth factor receptor (EGFR) monoclonal antibody (MAb), named Mint5, covalently linked to the type 1 ribosome-inactivating proteins (RlPs) ocymoidine (Ocy) and pyramidatine (Pyra) from Saponaria ocymoides and Vaccaria pyramidata respectively. Both antibody and toxins are shown to retain their respective biological properties upon chemical conjugation. The immunoconjugates exert specific inhibition of EGFR expressing target cell proliferation and protein synthesis in in vitro assays and also inhibit the growth of grafted human tumour cells in nude mice.
The clinical use of immunotoxins for the treatment of cancer is currently under evaluation worldwide. The therapeutic potentiality of immunotoxins and preclinical and clinical results over the last 20 years have been reviewed recently (Thrush et al, 1996) , indicating that, although immunotoxins seem promising for systemic therapy of haematological malignancies, a number of different problems still need to be solved, especially for the treatment of solid tumours. In particular, the refining of dose regimen and administration route, the combination with chemotherapy and the reduction of immunogenicity are the major goals of future research. In this paper, we describe the preparation of two new immunoconjugates made of an anti-epidermal growth factor receptor monoclonal antibody, named MintS, chemically linked to either ocymoidine or pyramidatine, toxins from Saponaria ocymoides and Vaccaria pyramidata respectively.
The epidermal growth factor (EGF) and its receptor play a critical role in the growth and regulation of many normal and malignant cell types. EGFR overexpression is a common feature in most carcinomas and correlates with poor prognosis (Fox et al, 1994) .
The potential value of EGFR as a target for the diagnosis and therapy of human tumours has been recognized for several years, and the use of anti-EGFR monoclonal antibodies may provide therapeutic tools in the treatment of tumours overexpressing the receptor (Ennis et al, 1991) .
Moreover, immunoconjugates of EGFR-specific monoclonal antibodies to either gelonin (Ozawa et al, 1989) or ricin A chain (Masui et al, 1989) were shown to reduce the growth of human tumour cells transplanted into athymic mice.
Mint5 is a murine monoclonal antibody raised against the human epidermoid carcinoma-derived cell line, A431. It recognizes an epitope associated with the ligand-binding site of EGFR and induces receptor internalization. Mint5 blocks EGF-induced EGFR tyrosine kinase activation in A43 1 cells and inhibits both in vitro and in vivo tumour growth. These characteristics suggest that MintS might be a valuable candidate for the treatment of EGFRoverexpressing tumours (Tosi et al, 1995) . In order to improve the cytolytic activity of MintS, two immunotoxins were prepared by linking MintS to the two recently described RIPs, ocymoidine and pyramidatine, from Saponaria ocymoides and Vaccaria pyramidata respectively (Bolognesi et al, 1995) . Ocymoidine and pyramidatine purified proteins run as a single band on polyacrylamide gel electrophoresis at relative molecular weights of about 30.2 and 28.0 kDa respectively. They show a basic pl around 9.5. The two proteins have the characteristics of the ribosome-inactivating proteins isolated from several plants belonging to the Caryophyllaceae family.
Many plant tissues contain proteins that specifically inhibit protein synthesis by inactivating eukaryotic ribosomes (Barbieri et al, 1993) . Most ribosome-inactivating proteins occur as monomeric proteins (type 1 RIPs) of molecular mass around 30 kDa, exhibit strong alkaline isoelectric points, sometimes exceeding 10 and may be N-glycosylated. In some cases RIP A chain is part of a heterodimeric protein (type 2 RIPs) in which it is joined to a galactose-binding lectin (B chain) by a single disulphide bond. Ricin and abrin are examples of such heterodimers and are among the most cytotoxic compounds known. RIPs from plants share the common property of inactivating ribosomes, hence inhibiting protein synthesis. This is owing to their highly specific RNA Nglycosidase activity that cleaves the glycosidic bond of adenine4324 in rat liver 28S rRNA (Endo et al, 1988) . This site of action is adjacent to the a-sarcin site of action (RIP from Aspergillus giganteus) and is contained in the exposed loop termed a-sarcin domain. The Biological characterization of two new immunoconjugates 823 latter toxin cleaves the phosphodiester bond between guanine4325 and adenine4326 in rat 28S rRNA, which also results in loss of ribosome function (Endo et al, 1983) .
MATERIALS AND METHODS Preparation of immunoconjugates
MintS MAb was purified by two ion exchange chromatography runs from conditioned serum-free media obtained by cultivation of hybridoma cells (kindly provided by Dr Colnaghi MI INT Milan) in a hollow fibre bioreactor (Acusyst R, Endotronics).
Pyramidatine and ocymoidine were purified from the seeds of Saponaria ocymoides and Vaccaria pyramidata, respectively, by a modification of a previously described method (Bolognesi et al, 1990) , including sequential ion-exchange chromatography on SSepharose and CM-Sepharose columns (Pharmacia, Sweden), followed by hydrophobic interaction chromatography on a phenylSepharose column (Pharmacia) for Saponaria ocymoides protein, or by filtration on Amicon PM1O membrane for Vaccaria pyramidata protein (Bolognesi et al, 1995) .
Immunoconjugates were prepared essentially according to a previously described method (Thorpe et al, 1988) , based on the use of 2-iminothiolane (2-IT).
In particular, activation of pyramidatine or ocymoidine was performed by dissolving RIP to a concentration of about 3 mg ml-' in 50 mm sodium borate buffer, pH 9.0. RIP labelled with 1251 (for a total of 106 c.p.m.) was added to this solution. After centrifugation to remove corpuscular material, 2-IT, dissolved immediately before use in 50 mm sodium borate buffer, pH 9.0, was added at 1-2 mm final concentration. After 60 min at 28°C, solid glycine was added to the final concentration of 200 mm, and after 15 min, the Ellman's reagent, dissolved in 50 pl of dimethylformamide immediately before use, was added to the final concentration of 2.5 mm. After a 15-min incubation at 28°C, the sample was loaded on a Sephadex G25 Coarse column (25 x 1.6 cm).
The protein peak was eluted in phosphate-buffered Saline (PBS: 0.14 M sodium chloride, 5 mm sodium phosphate buffer, pH 7.15), collected and the derivatization ratio was determined on a small amount of sample diluted 1:5 with PBS, by measuring the absorbances at 280 nm and 412 nm before and after addition of 1/10 (v/v) of a freshly prepared solution of 0.22 M 2-mercaptoethanol. The MintS monoclonal antibody at a concentration of 1-6 mg ml-' was reacted with 0.3 mM 2-IT, following the procedure described above.
The RIPs were concentrated under nitrogen using an Amicon concentrator and reduced by adding 1/10 in volume of 0.22 M 2-mercaptoethanol. The reduced toxins were loaded on a Sephadex G25 Coarse column (25 x 1.6 cm). The protein peak was collected in the concentrator containing the derivatized antibody. The reaction mixture was concentrated four times under nitrogen, with a total incubation time of 20 h at room temperature. The mixture was then loaded on a PBS-equilibrated Sephacryl S-200 HR column (96 x 2.2 cm) and the same buffer was used as eluent. By comparing the radioactivity elution profile with the profile of the absorbance at 280 nm, the various components of the mixture were identified. The RIP-antibody ratio in the pooled fractions containing the immunoconjugates was calculated by measuring the absorbance at 280 nm and the radioactivity of conjugate and of non-reacted RIPs. (Strocchi et al, 1992) (1:100 dilution, 4 h at 37°C), which crossreacts with ocymoidine and pyramidatine, followed by a 1251-labelled goat anti-rabbit IgG antiserum (105 c.p.m. per well, 4 h at 37°C). Bound c.p.m. were measured by a gamma-counter (Canberra Packard, USA) and background values obtained with unconjugated Mint5 were subtracted. All experiments were performed in triplicate.
RNA fragmentation assay
The RNA fragmentation assay was performed as described previously (Endo and Tsurugi, 1987) . Briefly, 35 gl of rabbit reticulocyte lysate (Promega C, Madison, WI, USA) were incubated in the presence of immunoconjugates at a concentration referred to as RIPs of 6 ,u g ml-' for 20 min at 37°C. The reaction was stopped by the addition of sodium dodecyl sulphate (SDS) to 0.5% final concentration. RNA was extracted with phenol, precipitated with 2.5 volumes of ethanol at -20°C for 1 h and resuspended in 20 pl of 1 M aniline acetate, pH. 4.5. After 30 min incubation on ice, RNA was extracted twice with ether and ethanol precipitated. Samples were resuspended in Tris borate EDTA buffer (TBE: 90 mM Tris/HCI, 90 mm boric acid, 3 mm EDTA, pH 8.0), 7 M urea, 0.1% bromophenol blue and 0.1% xylene cyanol. Electrophoresis was performed on 5% acrylamide gel containing 7 M urea and TBE, and staining was done with ethidium bromide as described previously (Stirpe et al, 1988) .
Inhibition of protein synthesis in rabbit reticulocyte lysate
The activity of toxins, both unconjugated and conjugated to MintS, was determined measuring the inhibition of protein synthesis by Immunotoxins (ng ml-1) (Wallac-OY-20101, Turku 10, Finland) . All experimental points were performed in quadruplicate.
As an alternative, 5 x 103 cells, plated at 0.1 ml per well, were incubated for 1 h at 4°C with 0.1 ml of different samples. Cells were then incubated for 2 h at 37°C to allow adherence. The plates were washed twice and 0.2 ml of fresh medium was added. After a 48-h incubation at 37°C, with an additional 6-h incubation in the presence of 0.5 ,u Ci of [3H]thymidine per well, radioactivity incorporation was measured as described above.
Inhibition of cell protein synthesis was evaluated on target human cell lines by measuring incorporation of [3H]leucine. The protocols used were the same as those for the inhibition of cell proliferation except that the cells were incubated with samples for 48 h and then 1 ,uCi of [3H]leucine was added to each well. After an additional 24 h, cells were harvested and the radioactivity was measured by liquid scintillation counting in a 5-counter (Canberra Packard). All experimental points were performed in quadruplicate. Figure 1 shows that Mint5 retains its binding property after chemical conjugation to ocymoidine or pyramidatine toxins. The specificity of the binding is confirmed by its absence in irrelevant target cells (data not shown).
The ribosome-inactivating property of ocymoidine and pyramidatine was double checked after chemical conjugation of toxins to Mint5 by both qualitative RNA fragmentation and quantitative protein synthesis inhibition tests. Figure 2 shows the electrophoretic analysis of rRNA from rabbit reticulocyte lysate after incubation with Mint5 immunoconjugates or with ricin. The arrow indicates the RNA fragments that are obtained by aniline treatment (+) following rRNA incubation with Mint-Pyra (lane 2), Mint-Ocy (lane 3), as well as ricin A chain (lane 4). The absence of fragments in samples not treated with aniline (-) confirms the RNA N-glycosidic activity of toxins.
Purified ocymoidine and pyramidatine either unconjugated or chemically linked to Mint5 MAb were analysed for their property of inhibiting cell-free protein synthesis by a rabbit reticulocyte lysate system. Results shown in Figure 3 indicate that unconjugated pyramidatine and ocymoidine inhibit 50% of protein synthesis at a concentration of 3.6 and 4.8 ng ml-' respectively (1.5 x 10-10 M and 1.58 x 10-10 M), and that this activity is partially reduced by chemical conjugation to Mint5, being 13.9 and 13.2 ng ml-' respectively (5.6 x 10-10 M and 4.0 x 10-10 M, referred to RIP). Unconjugated Mint5 alone does not affect protein synthesis (data 
Inhibition of cell proliferation and protein synthesis on target cells in vitro
The inhibition of cell proliferation and protein synthesis on A43 1 target cells was performed in vitro following two different procedures reported as protocols 1 and 2 (Figure 4 A and B) . In protocol 1, either toxin, immunotoxin or MAb was added at the time of cell seeding and stayed until the end of the culture, whereas in protocol 2, samples were removed after 1 h of incubation at 4°C followed by 2 h of incubation at 37'C. Figure 5 A shows the effect on A431 cell proliferation of either unconjugated toxin, Mint5 or of Mint-Ocy and Mint-Pyra immunoconjugates are 6.9 x 10-12 M and 1.8 x 10-12 M respectively. The immunoconjugates show lower activities if removed after initial incubation, as in protocol 2, with IC50 of 3 x 10-" M and 2.9 x 10-" M ( Figure 5B ). The inhibitory activities of unconjugated RIPs are also lower in protocol 2 experiments compared with protocol 1. In fact, IC50 for both ocymoidine and pyramidatine are >10-8 in protocol 2 and 6-9.6 x 10-'0 in protocol 1. These proliferation experiments indicate that the inhibitory activity of unconjugated Mint5, already reported by Tosi et al (1995) can be strongly potentiated when conjugated to RIP. Figure 5C shows that Mint-Ocy and Mint-Pyra added to the cell culture according to protocol inhibit A43 1 protein synthesis with an IC50 of 10-" M, whereas, when added according to protocol 2, IC50 values of 10-11 M and 1.3 x 10-" M, respectively, were obtained ( Figure 5D ). Analogously to the inhibition of cell proliferation, protein synthesis inhibition given by unconjugated ocymoidine and pyramidatine was lower in protocol 2 experiments with IC50 of 2 x 10 -M compared with protocol 1 values of IC50 2 x 10-8 M and 1.5 x 10-8 M respectively. The results from the above in vitro experiments suggest a different kinetic of action for immunotoxins on inhibiting proliferation or protein synthesis. In fact, maximal inhibition of proliferation requires the presence of immunoconjugate throughout the time of cell culture, whereas maximal inhibition of protein synthesis is reached after only 3 h of exposure at the beginning of the culture. In order to investigate Mint-Ocy and Mint-Pyra toxic activity as a function of different levels of EGFR expression, both proliferation and protein synthesis experiments were performed on A43 1, MCF7, SKBR-3 and IGR-OV-1 cell lines according to protocol 1 of Figure 4 . Table I shows the concentration of immunoconjugates inducing 50% inhibition of cell proliferation or protein synthesis on the different cell lines. These data indicate the absence of correlation between the toxic action of immunoconjugates and the number of EGFRs on the different cells. The specificity of immunotoxins for EGFR-expressing cells was confirmed on a Jurkat (EGFR-) cell line in which the toxic effect of the immunoconjugates was not greater than that of unconjugated toxins (data not shown).
In vivo experiments
The anti-tumour efficacy of Mint5 immunotoxins was studied by grafting A43 1 human tumour cells in athymic mice. The doses of immunoconjugates injected were based on the previously determined doses of ocymoidine and pyramidatine killing 50% of mice (LD50) resulting in 13.5 mg kg-' and 2.57 mg kg-' respectively.
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DISCUSSION
With the aim of obtaining selective toxic agents for cancer treatment, many RIPs have been conjugated to carrier molecules capable of delivering them to specific tumour cell populations. Antibodies, usually monoclonals, are the obvious choice for preparing conjugates, but hormones, growth factors and lectins have also been used as carriers for cancer therapy (Lappi et al, 1991; Wawrzynczak et al, 1991) . To date, ricin A has been the most frequently used RIP in preparing immunoconjugates, but more recently, several type 1 RIPs, namely gelonin, PAP saporin, momordin, bryodin and barley RIP, have been used to explore possible medical applications in cancer and autoimmune disease therapy, treatment of graft vs host disease, parasite killing, etc. (Barbieri et al, 1993) . For in vivo therapy, the linkage between the antigen-binding molecule and the toxin must be sufficiently stable to remain intact until the immunotoxin reaches its target cells and then the toxin must be released. A saporin-containing immunotoxin, prepared as described here, has been used previously in a clinical trial for the treatment of refractory Hodgkin's disease and proved to be very promising (Falini et al, 1992 (Baselga et al, 1993) . The conditions of treatment for in vivo experiments were fixed in order to achieve the maximum effect of immunoconjugates against a high number of grafted tumour cells. The adopted dose regimen induced weight loss in treated animals, probably owing to liver toxicity; thus, further pharmacokinetic and toxicological studies will be necessary to establish more controlled treatment protocols. Both in vitro and in vivo results indicate that an anti-tumour activity can be obtained by MintS/RIP conjugate. It is known that toxins and murine antibodies induce an immune response in treated patients (Frankel et al, 1995) . Therefore, the identification of new RIPs together with antibody 'humanization' procedures is particularly important in enlarging the list of immunotoxins for clinical use. Ocymoidine and pyramidatine were previously found to be immunologically cross-reactive only with RIPs from some plants belonging to the same Caryophyllaceae family, but not with RIPs from other plants (Bolognesi et al, 1995) . Data from our laboratory (not shown) indicate that, in spite of high N-terminal sequence homology, Ocy and Pyra exhibit only 7.5% of reciprocal crossreactivity, suggesting their possible use in therapy with sequential immunotoxin treatments. In addition to ocymoidine and pyramidatine, other RIPs are in preparation in our laboratory in order to overcome the immunogenicity problems related to therapeutic regimens requiring multiple administrations. Moreover, a humanized version of MintS antibody has been obtained recently in our laboratory showing substantially the same properties of parental MAb (Ferrer et al, 1997) .
The EGFR overexpression in some tumour cells compared with normal tissues has been indicated previously as an operational marker for tumour therapy with anti-EGFR monoclonal antibodies (Ennis et al, 1991) . Tosi et al (1995) show that MintS inhibits the proliferation of tumour cell lines to the same extent despite the difference in EGFR levels. The lack of quantitative discrimination of the levels of EGFR on target cells is also reported in the present paper with Mint-Ocy and Mint-Pyra immunoconjugates. In contrast to our observation, some immunoconjugates with ricin toxin have been reported to be able to induce a stronger in vitro inhibitory activity on those cell lines overexpressing EGFR (Masui et al, 1989) . Since, from our in vitro inhibitory experiments, the IGR-OV-1 and MCF7 cell lines, which are expressing similar EGFR levels, show different sensitivities to the toxic action of immunoconjugates (Table 1) , we believe that in vitro systems are not fully predictive of the biological effects and toxicity of these products in in vivo treatment. In the direction of specific targeting of toxins to EGFR of tumour cells, the generation of immunotoxins directed against an oncogenic mutant of EGFR has been published recently (Lorimer et al, 1995) . Mutated EGFR has been identified on gliomas, breast and lung carcinomas, and monoclonal antibodies directed against this mutant do not recognize the wild-type receptor expressed on normal cells.
In general, the toxicity data obtained from clinical trials with immunotoxins induce caution for their systemic use (Frankel et al, 1995) .
Possible therapeutic applications of Mint-Ocy and Mint-Pyra immunoconjugates could include the locoregional treatment of brain and bladder cancers. A recent communication reports successful treatment of glioblastoma with immunotoxins directed against the transferrin receptor (Laske et al, 1995) . Taking into consideration that glioblastoma cells overexpress EGFR, locoregional treatment with Mint-Ocy and Mint-Pyra immunoconjugates of residual tumour cells after surgery could also be considered. In addition, for this particular application, the induction of immune response would be prevented by the haematoencephalic barrier compartmentalization of immunoconjugates. Since it is generally accepted that recombinant immunotoxins are more stable and more efficient in tumour penetration compared with chemical immunoconjugates (Friedman et al, 1993) , the genes coding for both ocymoidine and pyramidatine have been isolated in Menarini Laboratories, and their expression in E. coli is in progress either alone or in combination with MintS single-chain
Fv to obtain recombinant single-chain immunotoxins.
